Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant... Oncol Ther (2017) 5:171–180 DOI 10.1007/s40487-017-0052-4 ORIGINAL RESEARCH Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors . . . . . Lin Shen Yan Sun Jian-Ming Xu Carlos Linn Qiao Wang Li-Qiang Yang Shu-Kui Qin Received: April 25, 2017 / Published online: September 25, 2017 The Author(s) 2017. This article is an open access publication safety in Chinese patients is limited. Our ABSTRACT objective is to determine the efficacy and safety of sunitinib in Chinese patients with ima- Introduction: Sunitinib is approved in China tinib-resistant/intolerant GIST. for treatment of gastrointestinal stromal tumors Methods: An open-label, single-arm, multicen- (GIST), after disease progression on, or intoler- ter, phase IV study was performed in Chinese ance to, imatinib. However, available data from patients with imatinib-resistant/intolerant prospective clinical trials on its efficacy and GIST. Sunitinib was administered orally in 6-week cycles of 4 weeks on-treatment (50 mg Enhanced content To view enhanced content for this once daily) and 2 weeks off-treatment. The pri- article go to http://www.medengine.com/Redeem/ mary endpoint was progression-free survival 6C4CF060434CFC2F. (PFS). Tumors were assessed every 6 weeks for the first 24 weeks and every 12 weeks thereafter. C. Linn (&) 36 Floor, CITIC http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors

Loading next page...
 
/lp/springer-journals/phase-iv-study-of-sunitinib-in-chinese-patients-with-imatinib-ZXyQVCAsi6
Publisher
Springer Journals
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-017-0052-4
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2017) 5:171–180 DOI 10.1007/s40487-017-0052-4 ORIGINAL RESEARCH Phase IV Study of Sunitinib in Chinese Patients with Imatinib-Resistant or Imatinib-Intolerant Gastrointestinal Stromal Tumors . . . . . Lin Shen Yan Sun Jian-Ming Xu Carlos Linn Qiao Wang Li-Qiang Yang Shu-Kui Qin Received: April 25, 2017 / Published online: September 25, 2017 The Author(s) 2017. This article is an open access publication safety in Chinese patients is limited. Our ABSTRACT objective is to determine the efficacy and safety of sunitinib in Chinese patients with ima- Introduction: Sunitinib is approved in China tinib-resistant/intolerant GIST. for treatment of gastrointestinal stromal tumors Methods: An open-label, single-arm, multicen- (GIST), after disease progression on, or intoler- ter, phase IV study was performed in Chinese ance to, imatinib. However, available data from patients with imatinib-resistant/intolerant prospective clinical trials on its efficacy and GIST. Sunitinib was administered orally in 6-week cycles of 4 weeks on-treatment (50 mg Enhanced content To view enhanced content for this once daily) and 2 weeks off-treatment. The pri- article go to http://www.medengine.com/Redeem/ mary endpoint was progression-free survival 6C4CF060434CFC2F. (PFS). Tumors were assessed every 6 weeks for the first 24 weeks and every 12 weeks thereafter. C. Linn (&) 36 Floor, CITIC

Journal

Oncology and TherapySpringer Journals

Published: Sep 25, 2017

References